Dehydroepiandrosterone supplementation in women with adrenal failure: Impact on twenty-four hour GH secretion and IGF-related parameters

Jens Juel Christiansen, Claus Højbjerg Gravholt, Sanne Fisker, Birgit Svenstrup, Paul Bennett, Johannes Veldhuis, Marianne Andersen, Jens S. Christiansen, Jens O.L. Jørgensen

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


OBJECTIVE: In women, GH secretion is strongly influenced by oestrogen status, whereas the role of androgens is unclear. We, therefore, examined GH secretory dynamics during low vs. normalized androgen levels in women with adrenal failure. PATIENTS: Ten females with adrenal failure (AF), mean age of 42 years (range 22-54 years). DESIGN: The effects of 8 days of oral dehydroepiandrosterone (DHEA; 50 mg/day) were studied in a double-blind placebo-controlled, cross-over design. A control group of healthy women was studied once without any treatment. MEASUREMENTS: Before and after each treatment period, blood was sampled for measurement of androgens, IGF-I, IGFBP-3 and GHBP. A 24-h GH profile with measurements every 20 min was performed at the end of each period. RESULTS: DHEA supplementation normalized the mean circulating levels of testosterone and androgen precursors. The secretory pattern of GH was unaltered during DHEA [placebo vs. DHEA; half-life 22.83 ± 1.24 vs. 21.45 ± 1.19 (min), P = 0.429; pulse frequency 9.9 ± 0.7 vs. 10.5 ± 0.5 (/24 h), P = 0.502; total production rate 62.27 ± 13.44 vs. 52.61 ± 7.06 (μg/l/day), P = 0.317]. Subgroup analysis, however, indicated that DHEA treatment increased GH secretion in patients not receiving oestrogen (n = 5), whereas the opposite was observed among patients receiving exogenous oestrogen derivatives (n = 5). Compared to the control group (CON), GH half-life was longer in AF (half-life CON: 16.48 ± 0.91, P = 0.001). The additional features of GH secretion were similar. Unexpectedly, the levels of IGF-I, IGFBP-3 and GHBP were elevated in the patients as compared to controls, without significant effects of DHEA [AF vs. CON. IGF-I: 186 ± 20 vs. 144 ± 7 (μg/l), P = 0.04; IGFBP-3: 5196 ± 224 vs. 3687 ± 212 (μg/l), P = 0.001; GHBP: 2.27 ± 0.25 vs. 1.41 ± 0.13 (nmol/l), P = 0.002]. CONCLUSION: (1) Short-term DHEA administration in women with adrenal failure normalizes the circulating levels of androgens without uniformly affecting the GH-IGF axis; (2) The observation that exogenous oestradiol may mask a stimulatory effect of DHEA on GH secretion merits future investigation.

Original languageEnglish (US)
Pages (from-to)461-469
Number of pages9
JournalClinical Endocrinology
Issue number4
StatePublished - Apr 1 2004

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Dehydroepiandrosterone supplementation in women with adrenal failure: Impact on twenty-four hour GH secretion and IGF-related parameters'. Together they form a unique fingerprint.

Cite this